MCID: ADM013
MIFTS: 48

Adamantinoma of Long Bones

Categories: Bone diseases, Cancer diseases, Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Adamantinoma of Long Bones

MalaCards integrated aliases for Adamantinoma of Long Bones:

Name: Adamantinoma of Long Bones 57 12 59 44
59 6 3 63 40
Long Bone Adamantinoma 12 15
Adamantinoma of Long Bone 12

Characteristics:

Orphanet epidemiological data:

59

Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Worldwide); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
adamantinoma of long bones:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare bone diseases


External Ids:

OMIM 57 102660
Disease Ontology 12 DOID:2775
MeSH 44 C562741
SNOMED-CT 68 56763007
Orphanet 59 ORPHA55881
ICD10 via Orphanet 34 C40.2
MESH via Orphanet 45 D050398
UMLS via Orphanet 74 C1367554
MedGen 42 C0334556
ICD10 33 H40-H42 H40
UMLS 73 C0334556

Summaries for Adamantinoma of Long Bones

PubMed Health : 63 About : Vision often worsens with age. In addition to this normal aging effect, people may also develop eye conditions that further impair their eyesight or even lead to blindness. Glaucoma is one of the more common eye diseases.The term "glaucoma" is used to describe a number of different eye conditions, all of which involve damage to the optic nerve. This leads to ever larger gaps in the field of vision, which often remain unnoticed at first. Your field of vision is what you can see when you look straight ahead, without moving your eyes. In advanced stages, your ability to see things sharply (visual acuity) also gets worse.The following information mainly covers the most common form of glaucoma, called primary open-angle glaucoma (POAG). It progresses slowly, and damage to the optic nerve will not cause vision problems for many years. Eye drops and surgery are the most common treatment options.

MalaCards based summary : Adamantinoma of Long Bones is related to osteofibrous dysplasia and tibial adamantinoma. An important gene associated with Adamantinoma of Long Bones is ZEB1 (Zinc Finger E-Box Binding Homeobox 1), and among its related pathways/superpathways are Mesodermal Commitment Pathway and MicroRNAs in cancer. The drugs Hydrocortisone acetate and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include Eye, bone and eye, and related phenotypes are pathologic fracture and hypercalcemia

Disease Ontology : 12 An adamantinoma that is located in the long bones and results in focal epithelial differentiation.

CDC : 3 Acanthamoeba is a microscopic, free-living ameba, or amoeba* (single-celled living organism), that can cause rare**, but severe infections of the eye, skin, and central nervous system. The ameba is found worldwide in the environment in water and soil. The ameba can be spread to the eyes through contact lens use, cuts, or skin wounds or by being inhaled into the lungs. Most people will be exposed to Acanthamoeba during their lifetime, but very few will become sick from this exposure. The three diseases caused by Acanthamoeba are:

Wikipedia : 76 Adamantinoma (from the Greek word adamantinos, meaning "very hard") is a rare bone cancer, making up... more...

Description from OMIM: 102660

Related Diseases for Adamantinoma of Long Bones

Diseases related to Adamantinoma of Long Bones via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
# Related Disease Score Top Affiliating Genes
1 osteofibrous dysplasia 11.5
2 tibial adamantinoma 11.2
3 breast cancer 10.6 CCND1 EZH2 GAS5 H19 HOTAIR HOTTIP
4 ovarian cancer 10.5 CCND1 GAS5 H19 HOTAIR HOXA11-AS MIR127
5 hepatocellular carcinoma 10.5 C20orf204 CCND1 GAS5 H19 HOTAIR HOTTIP
6 lung cancer 10.5 CCND1 GAS5 H19 HOTAIR HOTTIP HOXA11-AS
7 prostate cancer 10.5 CCND1 EZH2 GAS5 H19 HOTAIR HOTTIP
8 melanoma 10.5 GAS5 H19 HOTAIR MIR127 MIR141 MIR200A
9 esophageal cancer 10.5 C20orf204 CCND1 GAS5 H19 HOTAIR HOTTIP
10 colorectal cancer 10.5 CCND1 GAS5 H19 HOTAIR HOTTIP HOXA11-AS
11 gastric cancer 10.5 CCND1 GAS5 H19 HOTAIR HOTTIP HOXA11-AS
12 glioma 10.5 CCND1 GAS5 H19 HOTAIR HOTTIP HOXA11-AS
13 bladder cancer 10.5 CCND1 EZH2 GAS5 H19 HOTAIR HULC
14 kidney cancer 10.5 GAS5 H19 HOTAIR MIR141 MIR200B MIR200C
15 osteogenic sarcoma 10.5 GAS5 H19 HOTAIR HOTTIP HOXA11-AS HULC
16 cholangiocarcinoma 10.5 CCND1 H19 HULC MIR141 MIR200B UCA1
17 cervical cancer 10.5 CCND1 GAS5 H19 HOTAIR HOXA11-AS HULC
18 squamous cell carcinoma, head and neck 10.5 CCND1 GAS5 H19 HOTAIR MIR141 MIR200A
19 pancreatic ductal adenocarcinoma 10.5 H19 HOTAIR HOTTIP MIR141 UCA1
20 pancreatic cancer 10.5 CCND1 GAS5 H19 HOTAIR HOTTIP HULC
21 thyroid cancer 10.5 CCND1 GAS5 H19 HOTAIR UCA1
22 thyroid cancer, nonmedullary, 1 10.5 GAS5 H19 HOTAIR HOTTIP HULC
23 endometrial cancer 10.5 CCND1 GAS5 H19 HOTAIR MIR200C UCA1
24 renal cell carcinoma, nonpapillary 10.5 GAS5 H19 HOTAIR MIR141 MIR200C UCA1
25 oral squamous cell carcinoma 10.5 H19 HOTAIR MIR200B MIR200C UCA1
26 squamous cell carcinoma 10.5 CCND1 H19 HOTAIR UCA1
27 malignant glioma 10.4 GAS5 HOTAIR HOTTIP HOXA11-AS
28 myeloma, multiple 10.4 CCND1 GAS5 H19 HOTAIR UCA1
29 laryngeal squamous cell carcinoma 10.4 CCND1 H19 HOTAIR HOXA11-AS
30 endometriosis 10.4 H19 MIR141 MIR200A MIR200B
31 ovarian serous carcinoma 10.4 MIR141 MIR200A MIR200C
32 ovarian epithelial cancer 10.4 H19 HOTAIR HULC
33 nonalcoholic fatty liver disease 10.4 MIR200A MIR200B MIR200C MIR429
34 nasopharyngeal carcinoma 10.4 CCND1 GAS5 H19 HOTAIR HULC
35 diffuse large b-cell lymphoma 10.4 EZH2 HOTAIR HULC MIR127
36 lung cancer susceptibility 3 10.4 CCND1 GAS5 H19 HOTAIR MIR200B
37 leukemia, chronic myeloid 10.4 H19 HOTAIR HULC UCA1
38 gastrointestinal system cancer 10.4 CCND1 H19 HOTAIR
39 mantle cell lymphoma 10.4 CCND1 EZH2 GAS5
40 gastric cardia adenocarcinoma 10.4 H19 HOTAIR
41 gallbladder cancer 10.4 H19 HOTAIR UCA1
42 coronary heart disease 1 10.4 GAS5 H19 HOTTIP
43 glioblastoma 10.3 CCND1 GAS5 H19 HOTAIR
44 osteoarthritis 10.3 GAS5 H19 HOTAIR
45 bladder urothelial carcinoma 10.3 CCND1 GAS5 HOTAIR
46 b-cell lymphomas 10.2 CCND1 GAS5 HOTAIR
47 fibrous dysplasia 10.0
48 ossifying fibroma 10.0

Graphical network of the top 20 diseases related to Adamantinoma of Long Bones:



Diseases related to Adamantinoma of Long Bones

Symptoms & Phenotypes for Adamantinoma of Long Bones

Symptoms via clinical synopsis from OMIM:

57
Oncology:
adamantinoma of long bones


Clinical features from OMIM:

102660

Human phenotypes related to Adamantinoma of Long Bones:

59 32
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pathologic fracture 59 32 occasional (7.5%) Occasional (29-5%) HP:0002756
2 hypercalcemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003072
3 bone pain 59 32 frequent (33%) Frequent (79-30%) HP:0002653
4 neoplasm 32 HP:0002664

Drugs & Therapeutics for Adamantinoma of Long Bones

PubMedHealth treatment related to Adamantinoma of Long Bones: 63

Lowering high intraocular pressure can help to delay or stop the gradual progression of vision loss. Glaucoma can't be cured, though, because existing damage to the optic nerve can't be reversed. If someone has glaucoma and high intraocular pressure, it is usually treated using eye drops. Depending on the specific product, the eye drops are applied either once or several times a day.Surgery or laser therapy may be considered if the medication doesn't work, stops working after a while, or is not well tolerated.

Drugs for Adamantinoma of Long Bones (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
2
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4 Hormones Phase 4,Phase 3,Phase 2,Phase 1
5 Anti-Inflammatory Agents Phase 4,Phase 1
6 Hydrocortisone 17-butyrate 21-propionate Phase 4
7 glucocorticoids Phase 4,Phase 1
8 Hydrocortisone-17-butyrate Phase 4
9 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
10 Anesthetics Phase 4
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Antineoplastic Agents, Hormonal Phase 4,Phase 1,Not Applicable
13 Cortisol succinate Phase 4
14
Exenatide Approved, Investigational Phase 3,Phase 2 141758-74-9 15991534
15
Diazoxide Approved Phase 3,Phase 2 364-98-7 3019
16 Incretins Phase 3,Phase 2
17 Hypoglycemic Agents Phase 3,Phase 2
18 glucagon Phase 3
19 Glucagon-Like Peptide 1 Phase 3
20 Antihypertensive Agents Phase 3,Phase 2
21 Vasodilator Agents Phase 3,Phase 2
22
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
23
Trametinib Approved Phase 2 871700-17-3 11707110
24
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
25
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
26
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
27
Metformin Approved Phase 2 657-24-9 14219 4091
28
Memantine Approved, Investigational Phase 2 19982-08-2 4054
29
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
30
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
31
Methionine Approved, Nutraceutical Phase 2 63-68-3 6137
32
Camptothecin Experimental Phase 2 7689-03-4
33 Protein Kinase Inhibitors Phase 2
34 Anti-Infective Agents Phase 2,Phase 1
35 interferons Phase 2
36 Antiviral Agents Phase 2
37 Immunologic Factors Phase 2,Phase 1
38 Interferon-alpha Phase 2
39 Fluorodeoxyglucose F18 Phase 2
40 Radiopharmaceuticals Phase 2,Not Applicable
41 Oxytocics Phase 2
42 Insulin, Globin Zinc Phase 2
43 insulin Phase 2
44 Dopamine Agents Phase 2
45 Excitatory Amino Acids Phase 2
46 Excitatory Amino Acid Antagonists Phase 2
47 Antiparkinson Agents Phase 2
48 Neurotransmitter Agents Phase 2
49 Antineoplastic Agents, Phytogenic Phase 2
50 topoisomerase I inhibitors Phase 2

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
3 Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Completed NCT02860923 Phase 3 Exenatide;Placebo
4 Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3 DIAZOXIDE
5 Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma Recruiting NCT02367859 Phase 2 Dabrafenib;Trametinib
6 Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma Recruiting NCT03224767 Phase 2 Vemurafenib;Cobimetinib
7 Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma) Active, not recruiting NCT02842723 Phase 2
8 A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection Recruiting NCT02792582 Phase 2
9 Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery Active, not recruiting NCT01964300 Phase 2
10 A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection Active, not recruiting NCT01419067 Phase 2 ^1^8F-fluorodeoxyglucose;^1^1C-methionine
11 Intranasal Oxytocin in Hypothalamic Obesity Recruiting NCT02849743 Phase 2 Syntocinon;Placebo (for Syntocinon)
12 Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy Completed NCT00892073 Phase 2 Diazoxide;Metformin
13 An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury Completed NCT02063295 Phase 2 ZGN-440 sterile diluent;ZGN-440 for injectable suspension
14 Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor Completed NCT01484873 Phase 2 Exenatide
15 Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Recruiting NCT03194906 Phase 2 Memantine
16 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2 Methionine
17 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
18 Neuromodulation for Hypothalamic Obesity Withdrawn NCT03708913 Phase 1
19 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
20 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
21 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
22 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
23 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
24 Stereotactic Radiosurgery in Treating Patients With Brain Tumors Completed NCT00019578 Phase 1
25 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
26 Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors Terminated NCT00110032 Phase 1 EF5
27 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
28 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
29 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
30 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
31 Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma Unknown status NCT00949156
32 Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy Recruiting NCT03610906
33 Examination of Sleep and Family Functioning in Pediatric Craniopharyngioma Patients Recruiting NCT03330080
34 Social Participation After Childhood Craniopharyngioma Completed NCT03139526
35 Prospective Study of Children and Adolescents With Craniopharyngioma Recruiting NCT01272622 Not Applicable
36 1.5T Intraoperative MR Imaging in Craniopharyngiomas Completed NCT01206543 Not Applicable
37 Weight Gain in Surgically Treated Adult-onset Craniopharyngioma Completed NCT01968603
38 Sleep Wake and Melatonin Pattern in Craniopharyngioma Completed NCT01881854
39 Observation of Young Patients Who Are Undergoing Surgery for Craniopharyngioma Completed NCT00258453 Not Applicable
40 Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Withdrawn NCT02194452 Not Applicable
41 Molecular-Guided Therapy for Childhood Cancer Active, not recruiting NCT02162732 Not Applicable
42 Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Completed NCT00919750
43 Collecting and Storing Tissue From Young Patients With Cancer Completed NCT00898755

Search NIH Clinical Center for Adamantinoma of Long Bones

Cochrane evidence based reviews: adamantinoma of long bones

Genetic Tests for Adamantinoma of Long Bones

Anatomical Context for Adamantinoma of Long Bones

MalaCards organs/tissues related to Adamantinoma of Long Bones:

41
Bone, Eye, Lung, Skin, Breast, Colon, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Adamantinoma of Long Bones:

19
The Long Bones
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Adamantinoma of Long Bones:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Ganglion Cell Layer Mature Ganglion Cells Affected by disease

Publications for Adamantinoma of Long Bones

Articles related to Adamantinoma of Long Bones:

(show top 50) (show all 1021)
# Title Authors Year
1
Influence of carbonate on sequestration of U(VI) on perovskite. ( 30342289 )
2019
2
Synergistic effect of surface plasmon resonance, Ti3+ and oxygen vacancy defects on Ag/MoS2/TiO2-x ternary heterojunctions with enhancing photothermal catalysis for low-temperature wastewater degradation. ( 30342291 )
2019
3
Chemical and mineral composition of fly ashes from home furnaces, and health and environmental risk related to their presence in the environment. ( 30342402 )
2019
4
Investigation of gamma strength functions and level density models effects on photon induced reaction cross-section calculations for the fusion structural materials 46,50Ti, 51V, 58Ni and 63Cu. ( 30368053 )
2019
5
Field study in an urban environment of simultaneous self-cleaning and hydrophobic nanosized TiO2-based coatings on stone for the protection of building surface. ( 30373068 )
2019
6
Simultaneous electro-oxidation and in situ electro-peroxone process for the degradation of refractory organics in wastewater. ( 30384256 )
2019
7
PLGA-amoxicillin-loaded layer formed on anodized Ti alloy as a hybrid material for dental implant applications. ( 30423788 )
2019
8
The design of additively manufactured lattices to increase the functionality of medical implants. ( 30423778 )
2019
9
Microstructure, mechanical properties and springback behaviour of Ti‑6Al‑4V alloy connection rod for spinal fixation device. ( 30423767 )
2019
10
Comparative study on Ti-Nb binary alloys fabricated through spark plasma sintering and conventional P/M routes for biomedical application. ( 30423747 )
2019
11
Anti-bacterium influenced corrosion effect of antibacterial Ti-3Cu alloy in Staphylococcus aureus suspension for biomedical application. ( 30423720 )
2019
12
Investigation of the wear and corrosion behaviors of Ti5Al2.5Fe and Ti6Al4V alloys produced by mechanical alloying method in simulated body fluid environment. ( 30423718 )
2019
13
Effects of acid-alkali treatment on bioactivity and osteoinduction of porous titanium: An in vitro study. ( 30423702 )
2019
14
Nanostructured titanium surfaces fabricated by hydrothermal method: Influence of alkali conditions on the osteogenic performance of implants. ( 30423681 )
2019
15
Influence of the crosstalk on the intensity of HAADF-STEM images of quaternary semiconductor materials. ( 30417387 )
2019
16
Phase-coherent transport in selectively grown topological insulator nanodots. ( 30499462 )
2019
17
Study on Microstructure of Nb-Ti Based Alloy by Groove Rolling Process. ( 30487009 )
2019
18
Preparation and Photocatalytic Properties of ZnO Deposited TiO₂ Nanotube Arrays by Anodization. ( 30486949 )
2019
19
Sol-gel preparation of titanium (IV)-immobilized hierarchically porous organosilica hybrid monoliths. ( 30482300 )
2019
20
Enhancement of municipal sludge dewaterability by electrochemical pretreatment. ( 30473311 )
2019
21
Evaluation of the Hot Workability of Commercially Pure Ti Using Hot Torsion Tests. ( 30469264 )
2019
22
Porous TiO₂ Nanotube Arrays for Drug Loading and Their Elution Sensing. ( 30469258 )
2019
23
Effect of the Active Channel Thickness Variation in Amorphous In-Zn-Sn-O Thin Film Transistor. ( 30469246 )
2019
24
Brazing Characteristics and Bonding Strength of Pure Titanium Joints Brazed with Low-Melting Temperature Zi-17Ti-22Ni Filler Metal. ( 30469228 )
2019
25
Mitigation of Volume Expansion of Silica Anodes by Porous Titanium Dioxide Coating for Lithium-Ion Batteries. ( 30469216 )
2019
26
AC Conductivity and Dielectric Properties of (1-x)(0.94Bi0.5Na0.5TiO₃-0.06BaTiO₃)-xTa Lead Free Ceramics. ( 30469197 )
2019
27
Improvement of On/Off Current Ratio of Amorphous In-Ga-Zn-O Thin-Film Transistor with Off-Planed Source/Drain Electrodes. ( 30469186 )
2019
28
Improvement in Resistance Switching of SiC-Based Nonvolatile Memory by Solution-Deposited HfOx Thin Film. ( 30469171 )
2019
29
Surface modification of Ti-6Al-4V alloy for osseointegration by alkaline treatment and chitosan-matrix glass-reinforced nanocomposite coating. ( 30446109 )
2019
30
The "Race for the Surface" experimentally studied: In vitro assessment of Staphylococcus spp. adhesion and preosteoblastic cells integration to doped Ti-6Al-4V alloys. ( 30551304 )
2019
31
Assembled gold nanorods for the photothermal killing of bacteria. ( 30551299 )
2019
32
Axial Suspension Plasma Spraying: An ultimate technique to tailor Ti6Al4V surface with HAp for orthopaedic applications. ( 30551296 )
2019
33
An investigation of the fate and behaviour of a mixture of WO3 and TiO2 nanoparticles in a wastewater treatment plant. ( 30528029 )
2019
34
Comprehensive and Integrative Experimentation Setup for Large Animal Hybrid Valvular Heart Surgery. ( 30527481 )
2019
35
On the role of magnesium in a LiF:Mg,Ti thermoluminescent dosimeter. ( 30521487 )
2019
36
Microstructure and Electrochemical Behavior of TiO₂ Nanotubes Coated on Titanium-Based Substrate Before and After Thermal Treatment. ( 30501810 )
2019
37
Dispersion and Structure Analysis of Nanocrystalline Ti-mZrO₂ Composite Powder for Biomedical Applications. ( 30501783 )
2019
38
Phase transition and hardness evolution of a Ti-5Al-5Mo-1Fe-1Cr alloy subjected to isothermal aging. ( 30223177 )
2019
39
Functional Elements Coatings on Ti-6Al-4V Alloy by Plasma Electrolytic Oxidation for Biomaterials. ( 30360212 )
2019
40
Microstructure and Mechanical Properties of Functional Graded Ti-Al-Si-N-O Nanocomposite Films Deposited by Filtered Arc Ion Plating Technique. ( 30360206 )
2019
41
Influence of Oxidative Etching Solution Temperatures on the Surface Roughness and Wettability of a Titanium Alloy. ( 30360197 )
2019
42
MoS₂-TiC-C Nanocomposites as New Anode Materials for High-Performance Lithium-Ion Batteries. ( 30360188 )
2019
43
Enhanced Photocatalytic Activity of B, N-Codoped TiO₂ by a New Molten Nitrate Process. ( 30360161 )
2019
44
New methods for assessing electron storage capacity and redox reversibility of biochar. ( 30359952 )
2019
45
The influence of sonication on the oxidative stability and nutritional value of organic dry-fermented beef. ( 30388475 )
2019
46
Ti3C2 MXenes nanosheets catalyzed highly efficient electrogenerated chemiluminescence biosensor for the detection of exosomes. ( 30388560 )
2019
47
Late Shoulder-Arm Morbidity Using Ultrasound Scalpel in Axillary Dissection for Breast Cancer: A Retrospective Analysis. ( 30502293 )
2019
48
Use of a novel coupled-oxidation tubular reactor (COTR)/ NTP-DBD catalytic plasma in a synergistic electro-catalysis system for odorous mercaptans degradation. ( 30388689 )
2019
49
Biomonitoring and health risks assessment of trace elements in various age- and gender-groups exposed to road dust in habitable urban-industrial areas of Hefei, China. ( 30390454 )
2019
50
Toxicity beyond accumulation of Titanium after exposure of Mytilus galloprovincialis to spiked seawater. ( 30390458 )
2019

Variations for Adamantinoma of Long Bones

ClinVar genetic disease variations for Adamantinoma of Long Bones:

6 (show top 50) (show all 56)
# Gene Variation Type Significance SNP ID Assembly Location
1 MYOC NM_000261.1(MYOC): c.855G> T (p.Thr285=) single nucleotide variant Benign/Likely benign rs146606638 GRCh37 Chromosome 1, 171605725: 171605725
2 MYOC NM_000261.1(MYOC): c.855G> T (p.Thr285=) single nucleotide variant Benign/Likely benign rs146606638 GRCh38 Chromosome 1, 171636585: 171636585
3 MYOC NM_000261.1(MYOC): c.227G> A (p.Arg76Lys) single nucleotide variant Benign/Likely benign rs2234926 GRCh38 Chromosome 1, 171652385: 171652385
4 MYOC NM_000261.1(MYOC): c.227G> A (p.Arg76Lys) single nucleotide variant Benign/Likely benign rs2234926 GRCh37 Chromosome 1, 171621525: 171621525
5 CREBBP NM_004380.2(CREBBP): c.3698G> A (p.Arg1233Lys) single nucleotide variant Likely pathogenic rs1057518844 GRCh37 Chromosome 16, 3807289: 3807289
6 CREBBP NM_004380.2(CREBBP): c.3698G> A (p.Arg1233Lys) single nucleotide variant Likely pathogenic rs1057518844 GRCh38 Chromosome 16, 3757288: 3757288
7 ZEB1 NM_030751.5(ZEB1): c.973C> T (p.Arg325Ter) single nucleotide variant Pathogenic rs1057518956 GRCh37 Chromosome 10, 31809236: 31809236
8 ZEB1 NM_030751.5(ZEB1): c.973C> T (p.Arg325Ter) single nucleotide variant Pathogenic rs1057518956 GRCh38 Chromosome 10, 31520308: 31520308
9 MYOC NM_000261.1(MYOC): c.823A> T (p.Lys275Ter) single nucleotide variant risk factor rs879255525 GRCh38 Chromosome 1, 171636617: 171636617
10 MYOC NM_000261.1(MYOC): c.823A> T (p.Lys275Ter) single nucleotide variant risk factor rs879255525 GRCh37 Chromosome 1, 171605757: 171605757
11 MYOC NM_000261.1(MYOC): c.39T> G (p.Pro13=) single nucleotide variant Likely benign rs12082573 GRCh38 Chromosome 1, 171652573: 171652573
12 MYOC NM_000261.1(MYOC): c.39T> G (p.Pro13=) single nucleotide variant Likely benign rs12082573 GRCh37 Chromosome 1, 171621713: 171621713
13 MYOC NM_000261.1(MYOC): c.728C> A (p.Thr243Asn) single nucleotide variant Uncertain significance rs781655611 GRCh38 Chromosome 1, 171638599: 171638599
14 MYOC NM_000261.1(MYOC): c.728C> A (p.Thr243Asn) single nucleotide variant Uncertain significance rs781655611 GRCh37 Chromosome 1, 171607739: 171607739
15 MYOC NM_000261.1(MYOC): c.865G> A (p.Asp289Asn) single nucleotide variant Uncertain significance rs767627671 GRCh38 Chromosome 1, 171636575: 171636575
16 MYOC NM_000261.1(MYOC): c.865G> A (p.Asp289Asn) single nucleotide variant Uncertain significance rs767627671 GRCh37 Chromosome 1, 171605715: 171605715
17 MYOC NM_000261.1(MYOC): c.1188G> A (p.Glu396=) single nucleotide variant Likely benign rs61730975 GRCh38 Chromosome 1, 171636252: 171636252
18 MYOC NM_000261.1(MYOC): c.1188G> A (p.Glu396=) single nucleotide variant Likely benign rs61730975 GRCh37 Chromosome 1, 171605392: 171605392
19 MYOC NM_000261.1(MYOC): c.*71G> A single nucleotide variant Uncertain significance rs886045564 GRCh38 Chromosome 1, 171635854: 171635854
20 MYOC NM_000261.1(MYOC): c.*71G> A single nucleotide variant Uncertain significance rs886045564 GRCh37 Chromosome 1, 171604994: 171604994
21 MYOC NM_000261.1(MYOC): c.*241A> G single nucleotide variant Uncertain significance rs186880389 GRCh38 Chromosome 1, 171635684: 171635684
22 MYOC NM_000261.1(MYOC): c.*241A> G single nucleotide variant Uncertain significance rs186880389 GRCh37 Chromosome 1, 171604824: 171604824
23 MYOC NM_000261.1(MYOC): c.440G> A (p.Arg147Gln) single nucleotide variant Uncertain significance rs114283307 GRCh38 Chromosome 1, 171652172: 171652172
24 MYOC NM_000261.1(MYOC): c.440G> A (p.Arg147Gln) single nucleotide variant Uncertain significance rs114283307 GRCh37 Chromosome 1, 171621312: 171621312
25 MYOC NM_000261.1(MYOC): c.477A> G (p.Leu159=) single nucleotide variant Likely benign rs61730977 GRCh38 Chromosome 1, 171652135: 171652135
26 MYOC NM_000261.1(MYOC): c.477A> G (p.Leu159=) single nucleotide variant Likely benign rs61730977 GRCh37 Chromosome 1, 171621275: 171621275
27 MYOC NM_000261.1(MYOC): c.224A> G (p.Gln75Arg) single nucleotide variant Uncertain significance rs886045568 GRCh38 Chromosome 1, 171652388: 171652388
28 MYOC NM_000261.1(MYOC): c.224A> G (p.Gln75Arg) single nucleotide variant Uncertain significance rs886045568 GRCh37 Chromosome 1, 171621528: 171621528
29 MYOC NM_000261.1(MYOC): c.568G> T (p.Asp190Tyr) single nucleotide variant Uncertain significance rs201930435 GRCh38 Chromosome 1, 171652044: 171652044
30 MYOC NM_000261.1(MYOC): c.568G> T (p.Asp190Tyr) single nucleotide variant Uncertain significance rs201930435 GRCh37 Chromosome 1, 171621184: 171621184
31 MYOC NM_000261.1(MYOC): c.975G> A (p.Thr325=) single nucleotide variant Likely benign rs61730976 GRCh38 Chromosome 1, 171636465: 171636465
32 MYOC NM_000261.1(MYOC): c.975G> A (p.Thr325=) single nucleotide variant Likely benign rs61730976 GRCh37 Chromosome 1, 171605605: 171605605
33 MYOC NM_000261.1(MYOC): c.992C> T (p.Ser331Leu) single nucleotide variant Uncertain significance rs775982158 GRCh38 Chromosome 1, 171636448: 171636448
34 MYOC NM_000261.1(MYOC): c.992C> T (p.Ser331Leu) single nucleotide variant Uncertain significance rs775982158 GRCh37 Chromosome 1, 171605588: 171605588
35 MYOC NM_000261.1(MYOC): c.*188C> T single nucleotide variant Uncertain significance rs886045562 GRCh38 Chromosome 1, 171635737: 171635737
36 MYOC NM_000261.1(MYOC): c.*188C> T single nucleotide variant Uncertain significance rs886045562 GRCh37 Chromosome 1, 171604877: 171604877
37 MYOC NM_000261.1(MYOC): c.*331A> G single nucleotide variant Uncertain significance rs548121911 GRCh38 Chromosome 1, 171635594: 171635594
38 MYOC NM_000261.1(MYOC): c.*331A> G single nucleotide variant Uncertain significance rs548121911 GRCh37 Chromosome 1, 171604734: 171604734
39 MYOC NM_000261.1(MYOC): c.*426C> T single nucleotide variant Uncertain significance rs142425726 GRCh38 Chromosome 1, 171635499: 171635499
40 MYOC NM_000261.1(MYOC): c.*426C> T single nucleotide variant Uncertain significance rs142425726 GRCh37 Chromosome 1, 171604639: 171604639
41 MYOC NM_000261.1(MYOC): c.114G> A (p.Arg38=) single nucleotide variant Uncertain significance rs767644139 GRCh38 Chromosome 1, 171652498: 171652498
42 MYOC NM_000261.1(MYOC): c.114G> A (p.Arg38=) single nucleotide variant Uncertain significance rs767644139 GRCh37 Chromosome 1, 171621638: 171621638
43 MYOC NM_000261.1(MYOC): c.239C> A (p.Thr80Asn) single nucleotide variant Uncertain significance rs886045567 GRCh38 Chromosome 1, 171652373: 171652373
44 MYOC NM_000261.1(MYOC): c.239C> A (p.Thr80Asn) single nucleotide variant Uncertain significance rs886045567 GRCh37 Chromosome 1, 171621513: 171621513
45 MYOC NM_000261.1(MYOC): c.304T> A (p.Leu102Met) single nucleotide variant Uncertain significance rs140017103 GRCh38 Chromosome 1, 171652308: 171652308
46 MYOC NM_000261.1(MYOC): c.304T> A (p.Leu102Met) single nucleotide variant Uncertain significance rs140017103 GRCh37 Chromosome 1, 171621448: 171621448
47 MYOC NM_000261.1(MYOC): c.335A> G (p.Glu112Gly) single nucleotide variant Uncertain significance rs886045566 GRCh38 Chromosome 1, 171652277: 171652277
48 MYOC NM_000261.1(MYOC): c.335A> G (p.Glu112Gly) single nucleotide variant Uncertain significance rs886045566 GRCh37 Chromosome 1, 171621417: 171621417
49 MYOC NM_000261.1(MYOC): c.648G> A (p.Lys216=) single nucleotide variant Uncertain significance rs141584495 GRCh38 Chromosome 1, 171638679: 171638679
50 MYOC NM_000261.1(MYOC): c.648G> A (p.Lys216=) single nucleotide variant Uncertain significance rs141584495 GRCh37 Chromosome 1, 171607819: 171607819

Copy number variations for Adamantinoma of Long Bones from CNVD:

7 (show top 50) (show all 8854)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13322 1 1 124300000 Deletion Cancer
2 13338 1 1 124300000 Loss Cancer
3 13402 1 1 2300000 Gain or loss SKI Cancer
4 13748 1 1 27800000 Loss Cancer
5 14855 1 110683467 110690826 Gain or loss RBM15 Cancer
6 14882 1 11089178 11245151 Gain or loss FRAP1 Cancer
7 15022 1 111886577 112057624 Gain or loss RAP1A Cancer
8 15053 1 112169367 112371631 Insert KCND3 Cancer
9 15118 1 112811562 112865428 Gain or loss WNT2B Cancer
10 15156 1 113045271 113051548 Gain or loss RHOC Cancer
11 15168 1 113054138 113059473 Gain or loss PPM1J Cancer
12 15235 7 99974769 99991926 Amplification HRBL Cancer
13 15240 1 113734997 114030068 Gain or loss MAGI3 Cancer
14 15281 1 114238969 114352508 Amplification or deletion TRIM33 Cancer
15 15306 1 114548311 114558715 Amplification or deletion NRAS Cancer
16 15330 1 114736921 114855304 Gain or loss TRIM33 Cancer
17 15338 1 114736922 114855304 Amplification O75428 Cancer
18 15357 1 114911708 114925788 Amplification Q8TEE9 Cancer
19 15359 7 100009569 100021712 Amplification LRCH4 Cancer
20 15374 7 100021891 100036676 Amplification FBXO24 Cancer
21 15392 1 115048600 115061038 Gain or loss NRAS Cancer
22 15400 7 100037817 100043737 Amplification PCOLCE Cancer
23 15404 7 100047660 100050936 Amplification MOSPD3 Cancer
24 15409 7 100055974 100078338 Amplification TFR2 Cancer
25 15416 7 100078663 100091986 Amplification ACTL6B Cancer
26 15444 1 115630059 115682380 Gain or loss NGFB Cancer
27 15529 1 11657123 11674265 Gain or loss MAD2L2 Cancer
28 15602 7 100109310 100114728 Amplification GNB2 Cancer
29 15670 1 117922092 117959602 Deletion Cancer
30 15674 1 11796339 11809890 Deletion Cancer
31 19878 1 151853355 151856086 Amplification NUDT17 Cancer
32 19882 1 151857899 151873192 Amplification POLR3C Cancer
33 19885 1 151867173 151871137 Amplification ZNF364 Cancer
34 19887 1 151873149 151884603 Amplification CD160 Cancer
35 19891 1 151897777 151900929 Amplification PDZK1 Cancer
36 19895 1 151901139 151910103 Amplification GPR89 Cancer
37 19900 1 151917737 151933087 Amplification NP_001091085.1 Cancer
38 19914 1 151967167 152013179 Amplification Cancer
39 19927 1 152011742 152013179 Amplification NBPF11 Cancer
40 19928 1 152013454 152019257 Amplification FAM108A2 Cancer
41 19941 1 152045729 152161848 Amplification Q6ZRH3 Cancer
42 19962 1 152168601 152185796 Amplification NBPF12 Cancer
43 19964 1 152186775 152197725 Amplification PRKAB2 Cancer
44 19966 1 152198199 152206812 Amplification FMO5 Cancer
45 19969 1 152207003 152213463 Amplification CHD1L Cancer
46 19973 1 152213373 152217075 Amplification NM_207400 Cancer
47 19975 1 152220756 152225430 Amplification Cancer
48 19978 1 152229853 152231245 Amplification PPIAL4 Cancer
49 19980 1 152231790 152394216 Amplification NBPF16 Cancer
50 19991 1 152375215 152379476 Amplification or deletion MUC1 Cancer

Expression for Adamantinoma of Long Bones

Search GEO for disease gene expression data for Adamantinoma of Long Bones.

Pathways for Adamantinoma of Long Bones

Pathways related to Adamantinoma of Long Bones according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.04 CCND1 EZH2 MIR141 MIR200A
2 11.98 CCND1 EZH2 MIR141 MIR200A MIR200B MIR200C
3 10.65 MIR141 MIR200A MIR200B MIR200C MIR429
4 10.23 HOTAIR UCA1

GO Terms for Adamantinoma of Long Bones

Cellular components related to Adamantinoma of Long Bones according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.1 H19 MIR127 MIR141 MIR200A MIR200B MIR200C

Biological processes related to Adamantinoma of Long Bones according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.17 H19 MIR127 MIR141 MIR200A MIR200B MIR200C
2 negative regulation of epithelial cell differentiation GO:0030857 8.96 CCND1 ZEB1

Molecular functions related to Adamantinoma of Long Bones according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR141 MIR200A MIR200B MIR200C MIR429

Sources for Adamantinoma of Long Bones

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....